Concepedia

Christopher J. Ferreri

CJ

Statistics

Publications

22

Citations

961

H-Index

16

Active since

2022

Affiliations

Levine Cancer Institute(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

Stanford University

Huntsman Cancer Institute

Christopher J. Ferreri is an author at Levine Cancer Institute specializing in multiple myeloma therapy, immunotherapy, and multiple myeloma.

ORCID

Publications per year

2022–2025

22

Publications

22

Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

Doris K. Hansen, Surbhi Sidana, Lauren C. Peres et al. · Journal of Clinical Oncology · 2023 · 279 citations · Full text

, , +15

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana, Krina K. Patel, Lauren C. Peres et al. · Blood · 2024 · 124 citations · Full text

, , +14

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy

Christopher J. Ferreri, Michelle A.T. Hildebrandt, Hamza Hashmi et al. · Blood Cancer Journal · 2023 · 111 citations · Full text

, , +17

Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma

Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera et al. · Blood Cancer Journal · 2024 · 54 citations · Full text

, , +17

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

Surbhi Sidana, Lauren C. Peres, Hamza Hashmi et al. · Haematologica · 2023 · 41 citations · Full text

, , +15

1–5 of 22